– Phase 3 trial achieved primary endpoint, quickly and safely restoring platelet function in ticagrelor-treated patients undergoing urgent surgery or experiencing major bleeding  – Results presented today in Late-Breaking Clinical Trial Session at the American College of Cardiology Annual Scientific Session  SFJ Pharmaceuticals (SFJ) and SERB Pharmaceuticals (SERB) announced today the final results of the pivotal […]

SERB Pharmaceuticals (SERB) announces the publication of the largest and most comprehensive study to date of patients with high-dose methotrexate (MTX)- induced acute kidney injury (MTX-AKI) treated with and without Voraxaze® (glucarpidase).

Philadelphia, 9 December 2024: SERB Pharmaceuticals, a global specialty pharmaceutical company, is proud to announce that Aurlumyn™ (iloprost) Injection, the first FDA-approved treatment for severe frostbite in adults to reduce the risk of digit amputations, is now commercially available in the US.1 Aurlumyn ™ is available through specialty distribution by FFF Enterprises Inc. Customers interested […]